M.D. Anderson Cancer Center: Myelodysplastic Syndromes trials

The registry lists 148 Myelodysplastic Syndromes studies with M.D. Anderson Cancer Center as lead sponsor. 18 are open to participants now and 78 have results posted.

Phase 1 59Phase 2 115Phase 3 6No phase 6(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic SyndromeNot yet recruitingNCT07780565Phase 1
• A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)RecruitingNCT06616636Phase 1
• A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.RecruitingNCT06566742Phase 2
• A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)RecruitingNCT06548230Phase 1/2
• A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess BlastsRecruitingNCT05365035Phase 2
• Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
• ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT05010122Phase 1/2
• Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingNCT04708054Phase 2/3
• CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04493164Phase 2
• A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaRecruitingNCT04239157Phase 2
• Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationRecruitingNCT03683433Phase 2
• Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRecruitingNCT03661307Phase 1/2
• Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyRecruitingNCT03630991Phase 1
• Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesRecruitingNCT03471260Phase 1/2
• Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
• Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingNCT02115295Phase 2
• Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic SyndromeRecruitingNCT01624805Phase 2
• Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)RecruitingNCT01515527Phase 2
• Off-the-shelf NK Cells + SCT for Myeloid MalignanciesCompletedNCT05115630Phase 2Results posted
• Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1TerminatedNCT04874194Phase 1/2Results posted
• DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT04752163Phase 1/2Results posted
• Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeCompletedNCT04487106Phase 2Results posted
• 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/IICompletedNCT03941769Phase 1/2Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic SyndromeStatus unknownNCT03094637Phase 2Results posted
• Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeTerminatedNCT03067571Phase 2Results posted
• Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromeCompletedNCT03047993Phase 1/2Results posted
• Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and NeutropeniaCompletedNCT03019939Phase 2Results posted
• Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02953561Phase 1/2Results posted
• Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantCompletedNCT02684162Phase 2Results posted
• Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)TerminatedNCT02599649Phase 2Results posted
• Nivolumab in AML in Remission at High Risk for RelapseCompletedNCT02532231Phase 2Results posted
• Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT02469415Phase 2Results posted
• Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT02464657Phase 1/2Results posted
• Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02399917Phase 2Results posted
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results posted
• Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in RemissionTerminatedNCT02302846Phase 2Results posted
• Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)CompletedNCT02269280Phase 2Results posted
• Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD MutationCompletedNCT02196857Phase 2Results posted
• Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) FailureCompletedNCT02159872Phase 2Results posted
• Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)TerminatedNCT02010645Phase 2Results posted
• Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT01904136Phase 1/2Results posted
• Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)CompletedNCT01893372Phase 2Results posted
• Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT01893320Phase 1/2Results posted
• Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01892371Phase 1/2Results posted
• Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 ActivationCompletedNCT01891968Phase 2Results posted
• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesCompletedNCT01823198Phase 1/2Results posted
• Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 RiskCompletedNCT01720225Phase 2Results posted
• E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic SyndromesCompletedNCT01692197Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01664897Phase 2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)TerminatedNCT01542684Phase 2Results posted
• Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT01471444Phase 3Results posted
• Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01444742Phase 2Results posted
• SB1518 for Patients With Myelodysplastic Syndrome (MDS)TerminatedNCT01436084Phase 2Results posted
• Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic SyndromeCompletedNCT01289457Phase 1/2Results posted
• Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01272245Phase 2Results posted
• Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic SyndromeCompletedNCT01254890Phase 1/2Results posted
• Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)TerminatedNCT01222195Phase 2Results posted
• Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)TerminatedNCT01191749Phase 2Results posted
• 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)CompletedNCT01038635Phase 1/2Results posted
• Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01019317Phase 2Results posted
• Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT00968071Phase 2Results posted
• Ondansetron Versus Aprepitant Plus Ondansetron for EmesisCompletedNCT00954941Phase 2Results posted
• Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT00948064Phase 2Results posted
• Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)TerminatedNCT00939159Phase 2Results posted
• Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)CompletedNCT00903760Phase 2Results posted
• PR1 Vaccination in Myelodysplastic Syndrome (MDS)TerminatedNCT00893997Phase 2Results posted
• Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)CompletedNCT00887068Phase 3Results posted
• Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)CompletedNCT00882102Phase 2Results posted
• Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic SyndromeCompletedNCT00806598Phase 2Results posted
• Bendamustine in Acute Leukemia and MDSTerminatedNCT00790855Phase 1/2Results posted
• Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT00778375Phase 2Results posted
• Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
• INCB018424 in Patients With Advanced Hematologic MalignanciesCompletedNCT00674479Phase 2Results posted
• Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00656617Phase 2Results posted
• A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDSCompletedNCT00656448Phase 3Results posted
• Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)CompletedNCT00569010Phase 1/2Results posted
• Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDSCompletedNCT00520468Phase 2Results posted
• Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)TerminatedNCT00506948Phase 2Results posted
• Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT00480987Phase 1/2Results posted
• Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic SyndromeCompletedNCT00475020Phase 2Results posted
• IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeCompletedNCT00469144Phase 3Results posted
• Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid LeukemiaCompletedNCT00469014Phase 2Results posted
• 2 Arm Study of Clofarabine IV in MDS PatientsCompletedNCT00422032Phase 2Results posted
• Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal InfectionsCompletedNCT00418951Phase 2Results posted
• Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)CompletedNCT00414310Phase 2Results posted
• Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) PatientsCompletedNCT00382590Phase 2Results posted
• Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeCompletedNCT00360672Phase 2Results posted
• Phase II 5-Azacytidine Plus VPA Plus ATRACompletedNCT00326170Phase 2Results posted
• Oral Clofarabine Study in Patients With Myelodysplastic SyndromeCompletedNCT00299156Phase 2Results posted
• Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)CompletedNCT00255346Phase 2Results posted
• Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine FailureTerminatedNCT00113321Phase 2Results posted
• Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).CompletedNCT00088218Phase 2Results posted
• Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)CompletedNCT00067808Phase 2Results posted
• Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)CompletedNCT00067028Phase 2Results posted
• A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)Active, not recruitingNCT06113302Phase 2
• A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous CladribineTerminatedNCT06021600Phase 1
• Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating AgentsCompletedNCT05030675Phase 1
• Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT04734990Phase 1/2